Determination of lornoxicam in pharmaceutical preparations by zero and first order derivative UV spectrophotometric methods

Pharmazie

Volumn 60, Issue 6, 2005, Pages 421-425

  Nemutlu, Emirhan ^a   Demircan, S ^a   Kir, S ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

LORNOXICAM; SODIUM HYDROXIDE;

ACCURACY; ARTICLE; DRUG DETERMINATION; DRUG DOSAGE FORM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; QUALITY CONTROL; TABLET; ULTRAVIOLET SPECTROPHOTOMETRY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALIBRATION; HYDROGEN-ION CONCENTRATION; INDICATORS AND REAGENTS; PHARMACEUTICAL SOLUTIONS; PIROXICAM; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, ULTRAVIOLET; TABLETS;

EID: 22044435266     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Balfour JA, Fitton A, Barradell LB (1996) Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 51: 639-657.
2. Bareggi SR, Gambaro V, Valenti M, Benvenuti C (1997) Absorption of oral lornoxicam in healthy volunteers using a granular formulation in comparison with standard tablets. Arzneimittelforschung 47: 755-757.
3. Bebewy LI (1998) Stability-indicating method for the determination of meloxicam and tetracaine hydrochloride in presence of their degradation products. Spectrosc Lett 31: 797-820.
4. Castro D, Moreno MA, Torrado S, Lastres JL (1999) Comparison of derivative spectrophotometric and liquid chromatograpic methods for the determination of omeprazole in aqueous solutions during stability studies. J Pharm Biomed Anal 21: 291-298.
5. Dittrich P, Radhofer-Welte S, Magometschnigg D, Kukovetz WR, Mayerhofer S, Ferbe HP (1990) The effect of concomitantly administered antacids on the bioavailability of lornoxicam, a novel highly potent NSAID. Drugs Exp Clin Res 16: 57-62.
6. Ghoneim MM, Beltagi AM, Radi (2002) A square-wave adsorptive stripping voltammetric determination of the anti-inflammatory drug lornoxicam. Anal Sci 18: 183-186.
7. ICH Topic Q2A, Validation of Analytical Procedures: Methodology, CPMP/ICH/281/95.
8. Joseph-Charles J, Bertucat M (1999) Simultaneous high performance liquid chromatographic analysis of non-steroidal anti-inflammatory oxicams in pharmaceutical preparations. J Liq Chrom Rel Technol 22: 2009-2021.
9. Karljikovic-Rajic K, Novovic D, Marinkovic V, Agbaba D (2003) First-order UV-derivative spectrophotometry in the analysis of omeprazole and pantoprazole sodium salt and corresponding impurities. J Pharm Biomed Anal 32: 1019-1027.
10. Kohl C, Steinkellner M (2000) Prediction of pharmacokinetic drug/drug interactions from in vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos 28: 161-168.
11. Olkkola KT, Brunetto AV, Mattila MJ (1994) Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet 26: 107-120.
12. Radhofer-Welte S, Dittrich P (1998) Determination of the novel non-steroidal anti-inflammatory drug lornoxicam and its main metabolite in plasma and synovial fluid. J Chromatogr B Biomed Sci Appl 707: 151-159.
13. Sabry SM, Mahgoub H (1999) Voltammetric, spectrofluorimetric and spectrophotometric methods to determine flufenamic acid. J Pharm Biomed Anal 21: 993-1001.
14. Skjodt NM, Davies NM (1998) Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. Clin Pharmacokinet 34: 421-428.
15. Suwa T, Urano H, Shinohara Y, Kokatsu J (1993) Simultaneous high-performance liquid chromatographic determination of lornoxicam and its 5′-hydroxy metabolite in human plasma using electrochemical detection. J Chromatogr 617: 105-110.
16. Tsai RS, Carrupt PA, El Tayyar N, Giroud Y, Andrade P, Testa B, Bree F, Tillement JP (1993) Physicochemical and structural properties of non-steroidal anti-inflammatory oxicams. Helv Chim Acta 76: 842-854.
17. Wang L, Asghamejad M (2000) Second-derivative UV spectrometric determination of simvastatin in its tablet dosage form. J Pharm Biomed Anal 21: 1243-1248.